António Pregueiro

Vice President Life Sciences Europe at HighPoint Solutions

António Pregueiro, PhD has over 12 years of experience in the pharmaceutical and biotechnology industries combined with a strong research background prior to his business career. Following his graduate training, he spent 5 years working in consulting firms focused in the life-sciences developing expertise in strategy, management and technology across several therapeutic areas. He worked globally, gaining experience in the US, Europe, South America, Russia and the Middle East. He then spent 8 years working in biotech and pharmaceutical companies across functions in analytics, marketing and operations, at companies like Amgen, Bausch & Lomb and Takeda. In his most recent industry position at Takeda he was the head of a business unit for a EU5 country with full P&L responsibility and leading a sales and marketing organization responsible for launching the company´s flagship biologic product.

Prior to that role, Dr Pregueiro was Head of Business Operations and Implementation transforming Takeda into a specialty pharmaceutical company through implementation of business operations, brand and customer enablement strategies. Prior to Takeda, he spent his career in both consulting and industry working at firms such as Trinity Partners, IMS Health, Amgen, and Bausch & Lomb. During this period he worked globally, gaining experience in the US, Europe, South America, Russia and the Middle East working across functions in analytics, marketing and operations spanning a broad range of therapeutic areas.

He was trained as a scientist, receiving a dual-honours BSc in Biochemistry and Genetics from the University of Sheffield in the UK in 1998. He conducted his doctoral research in the Molecular and Cell Biology graduate program at Dartmouth Medical School in the US, where he received his PhD in 2004. Dr. Pregueiro’s doctoral research involved identification of a novel molecular connection between biological clocks and DNA damage checkpoints involved in cancer development. His publications include articles in PNAS and Science.


Title: Biosimilars: A market to grow

  • Biosimilars: current state and future challenges
  • Leading companies and key drivers
  • Market Opportunities and Forecast